Protagonist Therapeutics Inc Cash Flow Conversion Efficiency
Protagonist Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Protagonist Therapeutics Inc (PTGX) has a cash flow conversion efficiency ratio of -0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.94 Million) by net assets ($645.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Protagonist Therapeutics Inc (2014–2024)
Cash flow conversion efficiency of Protagonist Therapeutics Inc from 2014 to 2024. This chart illustrates how Protagonist Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Protagonist Therapeutics Inc stock quote for real-time trading data and today's change.
Protagonist Therapeutics Inc Cash Flow Conversion Ratio Explained
Protagonist Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Protagonist Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Protagonist Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of Protagonist Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Phillips Edison & Co Inc
NASDAQ:PECO
|
0.044x |
|
Sweco AB (publ)
ST:SWEC-B
|
-0.005x |
|
Zhejiang Supor Co Ltd
SHE:002032
|
0.153x |
|
MINTH GRP LTD UNSP.ADR/20
F:M3I0
|
N/A |
|
WinWay Technology Co. Ltd
TW:6515
|
0.020x |
|
37 Interactive Entertainment Network Technology Group Co Ltd
SHE:002555
|
0.090x |
|
Scout24 AG
XETRA:G24
|
0.247x |
|
UNIQA Insurance Group AG
VI:UQA
|
0.072x |
Annual Cash Flow Conversion Efficiency for Protagonist Therapeutics Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Protagonist Therapeutics Inc from 2014 to 2024. Review Protagonist Therapeutics Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $675.29 Million | $184.15 Million | 0.273x | +230.72% |
| 2023-12-31 | $336.68 Million | $-70.24 Million | -0.209x | +58.41% |
| 2022-12-31 | $215.61 Million | $-108.14 Million | -0.502x | -39.50% |
| 2021-12-31 | $300.02 Million | $-107.86 Million | -0.360x | -38.69% |
| 2020-12-31 | $279.61 Million | $-72.48 Million | -0.259x | +50.08% |
| 2019-12-31 | $79.96 Million | $-41.53 Million | -0.519x | -16.99% |
| 2018-12-31 | $112.52 Million | $-49.95 Million | -0.444x | -1483.01% |
| 2017-12-31 | $120.63 Million | $3.87 Million | 0.032x | +109.38% |
| 2016-12-31 | $87.56 Million | $-29.97 Million | -0.342x | +77.16% |
| 2015-12-31 | $9.60 Million | $-14.38 Million | -1.499x | -54.01% |
| 2014-12-31 | $7.96 Million | $-7.74 Million | -0.973x | -- |
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical tri… Read more